Background: The epidemiology of Mycoplasma pneumoniae (Mp) among US children (<18 years) hospitalized with community-acquired pneumonia (CAP) is poorly understood. Methods: In the Etiology of Pneumonia in the Community study, we prospectively enrolled 2254 children hospitalized with radiographically confirmed pneumonia from January 2010-June 2012 and tested nasopharyngeal/oropharyngeal swabs for Mp using real-time polymerase chain reaction (PCR). Clinical and epidemiological features of Mp PCR-positive and -negative children were compared using logistic regression. Macrolide susceptibility was assessed by genotyping isolates. Results: One hundred and eighty two (8%) children were Mp PCR-positive (median age, 7 years); 12% required intensive care and 26% had pleural effusion. No in-hospital deaths occurred. Macrolide resistance was found in 4% (6/169) isolates. Of 178 (98%) Mp PCR-positive children tested for copathogens, 50 (28%) had ≥1 copathogen detected. Variables significantly associated with higher odds of Mp detection included age (10-17 years: adjusted odds ratio [aOR], 10.7 [95% confidence interval {CI}, 5.4-21.1] and 5-9 years: aOR, 6.4 [95% CI, 3.4-12.1] vs 2-4 years), outpatient antibiotics ≤5 days preadmission (aOR, 2.3 [95% CI, 1.5-3.5]), and copathogen detection (aOR, 2.1 [95% CI, 1.3-3.3]). Clinical characteristics were non-specific. Conclusions: Usually considered as a mild respiratory infection, Mp was the most commonly detected bacteria among children aged ≥5 years hospitalized with CAP, one-quarter of whom had codetections. Although associated with clinically nonspecific symptoms, there was a need for intensive care in some cases. Mycoplasma pneumoniae should be included in the differential diagnosis for school-aged children hospitalized with CAP.
Background: The epidemiology of Mycoplasma pneumoniae (Mp) among US children (<18 years) hospitalized with community-acquired pneumonia (CAP) is poorly understood. Methods: In the Etiology of Pneumonia in the Community study, we prospectively enrolled 2254 children hospitalized with radiographically confirmed pneumonia from January 2010-June 2012 and tested nasopharyngeal/oropharyngeal swabs for Mp using real-time polymerase chain reaction (PCR). Clinical and epidemiological features of Mp PCR-positive and -negative children were compared using logistic regression. Macrolide susceptibility was assessed by genotyping isolates. Results: One hundred and eighty two (8%) children were Mp PCR-positive (median age, 7 years); 12% required intensive care and 26% had pleural effusion. No in-hospital deaths occurred. Macrolide resistance was found in 4% (6/169) isolates. Of 178 (98%) Mp PCR-positive children tested for copathogens, 50 (28%) had ≥1 copathogen detected. Variables significantly associated with higher odds of Mp detection included age (10-17 years: adjusted odds ratio [aOR], 10.7 [95% confidence interval {CI}, 5.4-21.1] and 5-9 years: aOR, 6.4 [95% CI, 3.4-12.1] vs 2-4 years), outpatient antibiotics ≤5 days preadmission (aOR, 2.3 [95% CI, 1.5-3.5]), and copathogen detection (aOR, 2.1 [95% CI, 1.3-3.3]). Clinical characteristics were non-specific. Conclusions: Usually considered as a mild respiratory infection, Mp was the most commonly detected bacteria among children aged ≥5 years hospitalized with CAP, one-quarter of whom had codetections. Although associated with clinically nonspecific symptoms, there was a need for intensive care in some cases. Mycoplasma pneumoniae should be included in the differential diagnosis for school-aged children hospitalized with CAP.
Authors: Louise K Francois Watkins; Daniel Olson; Maureen H Diaz; Xia Lin; Alicia Demirjian; Alvaro J Benitez; Jonas M Winchell; Christine C Robinson; Kirk A Bol; Mary P Glodé; Samuel R Dominguez; Lisa A Miller; Preeta K Kutty Journal: Pediatr Infect Dis J Date: 2017-06 Impact factor: 2.129
Authors: Aaron M Harris; Anna M Bramley; Seema Jain; Sandra R Arnold; Krow Ampofo; Wesley H Self; Derek J Williams; Evan J Anderson; Carlos G Grijalva; Jonathan A McCullers; Andrew T Pavia; Richard G Wunderink; Kathryn M Edwards; Jonas M Winchell; Lauri A Hicks Journal: Open Forum Infect Dis Date: 2017-02-10 Impact factor: 3.835
Authors: A Bitnun; E L Ford-Jones; M Petric; D MacGregor; H Heurter; S Nelson; G Johnson; S Richardson Journal: Clin Infect Dis Date: 2001-05-21 Impact factor: 9.079
Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Xiao Li; T Prescott Atkinson; James Hagood; Chris Makris; Lynn B Duffy; Ken B Waites Journal: Pediatr Infect Dis J Date: 2009-08 Impact factor: 2.129
Authors: J W Dorigo-Zetsma; S A Zaat; P M Wertheim-van Dillen; L Spanjaard; J Rijntjes; G van Waveren; J S Jensen; A F Angulo; J Dankert Journal: J Clin Microbiol Date: 1999-01 Impact factor: 5.948
Authors: R C A de Groot; H Zhu; T Hoogenboezem; A C J M de Bruijn; E Eenjes; A E J 't Jong; A I Belo; S C Estevão; J J Bajramovic; R J Rottier; M Kool; A M C van Rossum; W W J Unger Journal: Infect Immun Date: 2022-07-11 Impact factor: 3.609
Authors: Patrick M Meyer Sauteur; Selina Krautter; Lilliam Ambroggio; Michelle Seiler; Paolo Paioni; Christa Relly; Riccarda Capaul; Christian Kellenberger; Thorsten Haas; Claudine Gysin; Lucas M Bachmann; Annemarie M C van Rossum; Christoph Berger Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079